CanBas Co., Ltd.
Notice of Approval to Commence European Phase 3 Clinical Trial for CBP501
Received approval to commence the European Phase 3 clinical trial for CBP501. The trial targets third-line pancreatic cancer; the primary endpoint is overall survival. The trial is planned in about 50 sites across 8 countries. No earnings guidance for the current fiscal year is disclosed; the company will disclose information as progress is made.
Key Figures
- Approval to commence Phase 3 clinical trial
- Indication: pancreatic cancer third-line treatment
- Trial size: approx. 180 people (total for 2 arms)
AI要約
Clinical Development Progress
CanBas Co., Ltd. announced that it obtained approval to commence the European Phase 3 clinical trial of CBP501. The trial is a randomized, open-label, multicenter study targeting third-line treatment for pancreatic cancer. The primary endpoint is overall survival (OS). The treatment arm will receive a triple combination of CBP501 + cisplatin + nivolumab, while the control arm will receive the best four regimens selected by investigators. The study is designed for approximately 180 patients across two arms, planned at about 50 sites in 8 countries. An interim analysis will be conducted when 25% of the data required for the final analysis have been collected. Preparations for trial initiation and contract signings are proceeding sequentially.
Earnings Outlook and Future Disclosure
Because the Phase 3 trial has the character of a pivotal study, there are strict constraints on data disclosure during the trial period. It is difficult to reasonably predict the impact of commencing this trial on the current fiscal year’s results, and therefore the company is not disclosing earnings guidance at this time. The company will timely disclose any impacts or outlook related to trial preparations and initiation as progress is made.
CanBas Co., Ltd.
Company overview · Stock price · Financial data · All IR